Identifying effect modifiers of systemic hydrocortisone treatment initiated 7-14 days after birth in ventilated very preterm infants on long-term outcome: secondary analysis of a randomised controlled trial

被引:0
作者
Halbmeijer, Nienke Marjolein [1 ,2 ]
Sonnaert, Michel [3 ]
Swarte, Renate M. [4 ]
Koopman-Esseboom, Corine [5 ]
van Stuijvenberg, Margriet [6 ]
Mulder-de Tollenaer, Susanne [7 ]
Tan, Ratna N. G. B. [8 ]
Mohns, Thilo [9 ]
Bruneel, Els [10 ]
Steiner, Katerina [11 ]
Kramer, Boris W. [12 ,13 ]
Debeer, Anne [14 ]
van Weissenbruch, Mirjam M. [2 ,15 ]
Marechal, Yoann [16 ]
Blom, Henry [17 ]
Plaskie, Katleen [18 ]
Offringa, Martin [1 ,19 ]
Merkus, Maruschka P. [20 ]
Onland, Wes [1 ,2 ]
Leemhuis, Aleid G. [1 ,2 ]
van Kaam, Anton H. [1 ,2 ]
机构
[1] Amsterdam UMC Locat Univ Amsterdam, Neonatol, POB 22700, NL-1100 DD Amsterdam, Netherlands
[2] Amsterdam Reprod & Dev, Res Inst, Amsterdam, Netherlands
[3] Univ Ziekenhuis Brussel, Neonatol, Brussels, Belgium
[4] Erasmus MC Sophia Childrens Hosp, Neonatol, Rotterdam, Netherlands
[5] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Neonatol, Utrecht, Netherlands
[6] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Neonatol, Groningen, Netherlands
[7] Isala Med Ctr, Neonatol, Zwolle, Netherlands
[8] Leiden Univ, Neonatol, Med Ctr, Leiden, Netherlands
[9] Women Mother & Child Ctr, Maxima Med Ctr, Neonatol, Veldhoven, Netherlands
[10] Ziekenhuis Oost Limburg, Neonatol, Genk, Belgium
[11] Amalia Childrens Hosp, Radboudumc Inst Hlth Sci, Neonatol, Nijmegen, Netherlands
[12] Univ Western Australia, Sch Womens & Infants Hlth, Crawley, WA, Australia
[13] Neuroplast BV, Res & Dev, Maastricht, Netherlands
[14] Univ Hosp Leuven, Neonatol, Leuven, Belgium
[15] Amsterdam UMC Locat Vrije Univ Amsterdam, Neonatol, Amsterdam, Netherlands
[16] Ctr Hosp Univ Charleroi, Neonatol, Charleroi, Belgium
[17] Univ Ziekenhuis Antwerpen, Neonatol, Edegem, Belgium
[18] St Augustinus Ziekenhuis, Neonatol, Antwerp, Belgium
[19] Univ Toronto, Hosp Sick Children, Neonatol & Child Hlth Evaluat Sci, Toronto, ON, Canada
[20] Amsterdam UMC Locat Univ Amsterdam, Epidemiol & Data Sci, Amsterdam, Netherlands
来源
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION | 2024年 / 109卷 / 02期
关键词
Neonatology; Infant Development; Respiratory Medicine; CARE PRACTICES; MORTALITY; MORBIDITY;
D O I
10.1136/archdischild-2023-325558
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To explore clinical effect modifiers of systemic hydrocortisone in ventilated very preterm infants for survival and neurodevelopmental outcome at 2 years' corrected age (CA). Design Secondary analysis of a randomised placebo-controlled trial. Setting Dutch and Belgian neonatal intensive care units. Patients Infants born <30 weeks' gestational age (GA), ventilator-dependent in the second week of postnatal life. Intervention Infants were randomly assigned to systemic hydrocortisone (cumulative dose 72.5 mg/kg; n=182) or placebo (n=190). Main outcome measures The composite of death or neurodevelopmental impairment (NDI) at 2 years' CA and its components. Candidate effect modifiers (GA, small for GA, respiratory index, sex, multiple births, risk of moderate/severe bronchopulmonary dysplasia or death) were analysed using regression models with interaction terms and subpopulation treatment effect pattern plots. Results The composite outcome was available in 356 (96.0%) of 371 patients (one consent withdrawn). For this outcome, treatment effect heterogeneity was seen across GA subgroups (<27 weeks: hydrocortisone (n=141) vs placebo (n=156), 54.6% vs 66.2%; OR 0.61 (95% CI 0.38 to 0.98); >= 27 weeks: hydrocortisone (n=30) vs placebo (n=31), 66.7% vs 45.2%; OR 2.43 (95% CI 0.86 to 6.85); p=0.02 for interaction). This effect was also found for the component death (<27 weeks: 20.1% vs 32.1%; OR 0.53 (95% CI 0.32 to 0.90); =27 weeks: 28.1% vs 16.1%; OR 2.04 (95% CI 0.60 to 6.95); p=0.049 for interaction) but not for the component NDI. No differential treatment effects were observed across other subgroups. Conclusion This secondary analysis suggests that in infants <27 weeks' GA, systemic hydrocortisone may improve the outcome death or NDI, mainly driven by itscomponent death. There was insufficient evidence for other selected candidate effect modifiers.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 22 条
[21]   Early dexamethasone therapy in preterm infants: A follow-up study [J].
Yeh, TF ;
Lin, YJ ;
Huang, CC ;
Chen, YJ ;
Lin, CH ;
Lin, HC ;
Hsieh, WS ;
Lien, YJ .
PEDIATRICS, 1998, 101 (05) :art. no.-e7
[22]   Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes [J].
Yip, Wai-Ki ;
Bonetti, Marco ;
Cole, Bernard F. ;
Barcella, William ;
Wang, Xin Victoria ;
Lazar, Ann ;
Gelber, Richard D. .
CLINICAL TRIALS, 2016, 13 (04) :382-390